- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00545259
Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation
December 6, 2020 updated by: Novartis
An Open-label, Two-period, Multi-center, Single Dose Study to Assess the Pharmacokinetics of AEB071 in de Novo Liver Transplant Patients
The study will evaluate the pharmacokinetic profile of AEB071 in the immediate post-transplant period in patients who have undergone their first liver transplant.
Study Overview
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany
- Novartis Investigative Site
-
-
-
-
-
Padova, Italy
- Novartis Investigative Site
-
-
-
-
-
Zurich, Switzerland
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Primary liver transplant recipients.
- Transplanted liver functioning at an acceptable level by 24 h post-transplant
- Patients started on tacrolimus therapy within 12 h post-transplant
Exclusion Criteria:
- Previous transplantation or multiple organs transplantation
- Acute rejection
- Non-heart beating donor
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
AEB071
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
-Pharmacokinetic of AEB071 & its primary metabolite, AEE800 at predose & up to 72 hours post-operatively -Safety & tolerability (vital signs,ECGs,clinical lab evaluations,seroius/adverse events) -AEB071,AEE800 & tacrolimus in blood for both Periods
Time Frame: at predose & 16 timepoints post-dose
|
at predose & 16 timepoints post-dose
|
Secondary Outcome Measures
Outcome Measure |
---|
-Pharmacokinetics of tacrolimus in presence of AEB071 -Biliary excretion of AEB071 & primary metabolite (AEE800) from patients with a T-tube -Relationship of free drug concentration, α-1 acid glycoprotein concentration & pharmacokinetics AEB071
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Actual)
February 1, 2009
Study Registration Dates
First Submitted
October 15, 2007
First Submitted That Met QC Criteria
October 16, 2007
First Posted (Estimate)
October 17, 2007
Study Record Updates
Last Update Posted (Actual)
December 8, 2020
Last Update Submitted That Met QC Criteria
December 6, 2020
Last Verified
February 1, 2008
More Information
Terms related to this study
Other Study ID Numbers
- CAEB071B2101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on de Novo Liver Transplantation
-
Novartis PharmaceuticalsCompletedDe Novo Renal TransplantationNorway
-
Astellas Pharma IncCompletedDe Novo Kidney TransplantationBelgium, France, Netherlands, Spain, Sweden, Austria, Italy, Germany, United Kingdom, Hungary, Poland, Czech Republic
-
NovartisCompleted
-
Rigshospitalet, DenmarkCompletedLiver Transplant Disorder | De Novo Cancer
-
NovartisCompletedRenal Transplantation | de Novo Kidney Transplant RecipientsItaly
-
Astellas Pharma Korea, Inc.Completedde Novo Liver Transplant SubjectsKorea, Republic of
-
Astellas Pharma Korea, Inc.Completedde Novo Kidney TransplantationKorea, Republic of
-
Novartis PharmaceuticalsCompletedPharmacokinetics Study in de Novo Kidney TransplantationGermany
-
NovartisCompleted
-
University Children's Hospital BaselSwiss National Science Foundation; Fondation BotnarCompletedDe Novo Lipogenesis (DNL)Switzerland
Clinical Trials on AEB071
-
Novartis PharmaceuticalsCompletedUveal MelanomaUnited Kingdom, France, Netherlands, United States
-
Novartis PharmaceuticalsTerminatedDiffuse Large B-Cell LymphomaTaiwan, Netherlands, Hong Kong, Italy, Germany, United States, Spain, France, United Kingdom, Korea, Republic of
-
NovartisCompletedPanuveitis | Uveitis | Posterior UveitisUnited States
-
NovartisCompleted
-
Novartis PharmaceuticalsCompletedModerate and Severe Plaque PsoriasisUnited States, Argentina, Germany, Belgium, Italy, United Kingdom, Turkey, Guatemala, Australia
-
Array Biopharma, now a wholly owned subsidiary...TerminatedUveal MelanomaUnited States, France, Germany, Netherlands, Spain, United Kingdom
-
Columbia UniversityCompleted
-
Novartis PharmaceuticalsCompletedUlcerative ColitisGermany, United States, Denmark, Poland
-
Novartis PharmaceuticalsCompletedKidney TransplantationUnited States, United Kingdom, Germany, Belgium, Spain, Canada, Sweden